Li Ping, Xi Yuqian, Zhang Yanping, Samad Abdus, Lan Wenli, Wu Ya, Zhao Jiayu, Chen Guangxin, Wu Changxin, Xiong Qiuhong
Institutes of Biomedical Sciences, The Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education of China, The Key Laboratory of Medical Molecular Cell Biology of Shanxi Province, Shanxi University, Taiyuan 030006, China.
Department of Biochemistry, Abdul Wali Khan University Mardan, Mardan 23200, Pakistan.
Cells. 2024 Mar 1;13(5):437. doi: 10.3390/cells13050437.
Fabry disease (FD) is an X-linked recessive inheritance lysosomal storage disorder caused by pathogenic mutations in the gene leading to a deficiency of the enzyme alpha-galactosidase A (α-Gal A). Multiple organ systems are implicated in FD, most notably the kidney, heart, and central nervous system. In our previous study, we identified four mutations from four independent Fabry disease families with kidney disease or neuropathic pain: c.119C>A (p.P40H), c.280T>C (C94R), c.680G>C (p.R227P) and c.801+1G>A (p.L268fsX3). To reveal the molecular mechanism underlying the predisposition to Fabry disease caused by mutations, we analyzed the effects of these four mutations on the protein structure of α-galactosidase A using bioinformatics methods. The results showed that these mutations have a significant impact on the internal dynamics and structures of GLA, and all these altered amino acids are close to the enzyme activity center and lead to significantly reduced enzyme activity. Furthermore, these mutations led to the accumulation of autophagosomes and impairment of autophagy in the cells, which may in turn negatively regulate autophagy by slightly increasing the phosphorylation of mTOR. Moreover, the overexpression of these GLA mutants promoted the expression of lysosome-associated membrane protein 2 (LAMP2), resulting in an increased number of lysosomes. Our study reveals the pathogenesis of these four mutations in FD and provides a scientific foundation for accurate diagnosis and precise medical intervention for FD.
法布里病(FD)是一种X连锁隐性遗传性溶酶体贮积症,由该基因的致病性突变引起,导致α-半乳糖苷酶A(α-Gal A)缺乏。多个器官系统与FD有关,最显著的是肾脏、心脏和中枢神经系统。在我们之前的研究中,我们从四个患有肾脏疾病或神经性疼痛的独立法布里病家族中鉴定出四个突变:c.119C>A(p.P40H)、c.280T>C(C94R)、c.680G>C(p.R227P)和c.801+1G>A(p.L268fsX3)。为了揭示由这些突变导致法布里病易感性的分子机制,我们使用生物信息学方法分析了这四个突变对α-半乳糖苷酶A蛋白质结构的影响。结果表明,这些突变对GLA的内部动力学和结构有显著影响,所有这些改变的氨基酸都靠近酶活性中心,并导致酶活性显著降低。此外,这些突变导致细胞中自噬体的积累和自噬功能障碍,这可能反过来通过轻微增加mTOR的磷酸化对自噬产生负调节作用。此外,这些GLA突变体的过表达促进了溶酶体相关膜蛋白2(LAMP2)的表达,导致溶酶体数量增加。我们的研究揭示了FD中这四个突变的发病机制,并为FD的准确诊断和精准医疗干预提供了科学依据。